

Publication list of Olivier Michielin

1. Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P. & Speiser, D. E. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. *Proc Natl Acad Sci U S A* **112**, 6140-6145 (2015).
2. Michielin, O. & Hoeller, C. Gaining momentum: New options and opportunities for the treatment of advanced melanoma. *Cancer Treat Rev* (2015).
3. Moura, B., Homicsko, K., Berthod, G., Cerottini, J. P., Guggisberg, D., Gaide, O., Maillard, M. H. & Michielin, O. [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]. *Rev Med Suisse* **11**, 1108, 1110-4 (2015).
4. Rohrig, U. F., Majjigapu, S. R., Vogel, P., Zoete, V. & Michielin, O. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. *J Med Chem* (2015).
5. Rohrig, U. F., Majjigapu, S. R., Chambon, M., Bron, S., Pilotte, L., Colau, D., Van den Eynde, B. J., Turcatti, G., Vogel, P., Zoete, V. & Michielin, O. Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. *Eur J Med Chem* **84C**, 284-301 (2014).
6. Romano, E. & Michielin, O. Successes and limitations of targeted cancer therapy in melanoma. *Prog Tumor Res* **41**, 78-88 (2014).
7. Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J., van der Burg, S., Kapiteijn, E., Michielin, O., Romano, E., Linnemann, C., Speiser, D., Blank, C., Haanen, J. B. & Schumacher, T. N. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. *Sci Transl Med* **6**, 254ra128 (2014).
8. Bordry, N., Costa-Nunes, C. M., Cagnon, L., Gannon, P. O., Abed-Maillard, S., Baumgaertner, P., Murray, T., Letovanec, I., Lazor, R., Bouchaab, H., Rufer, N., Romano, E., Michielin, O. & Speiser, D. E. Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term surviving metastatic melanoma patient. *Cancer Immunol Res* (2014).
9. Choudhary, V., Darwiche, R., Gfeller, D., Zoete, V., Michielin, O. & Schneiter, R. The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate. *J Lipid Res* **55**, 883-894 (2014).
10. Coukos, G., Michielin, O., Dietrich, P. & Aapro, M. [In process citation]. *Rev Med Suisse* **10**, 1099-1100 (2014).
11. Michielin, O. & Coukos, G. [Genomics medicine and oncology]. *Praxis (Bern 1994)* **103**, 591-596 (2014).
12. Peters, S., Bouchaab, H., Zimmerman, S., Bucher, M., Gaide, O., Letovanec, I., Homicsko, K. & Michielin, O. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. *Melanoma Res* **24**, 496-500 (2014).
13. Daina, A., Michielin, O. & Zoete, V. iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. *J Chem Inf Model* **54**, 3284-3301 (2014).
14. Romano, E., Michielin, O., Voelter, V., Laurent, J., Bichat, H., Stravodimou, A., Romero, P., Speiser, D. E., Triebel, F., Leyvraz, S. & Harari, A. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. *J Transl Med* **12**, 97 (2014).
15. Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E. & Speiser, D. E. Frequencies of circulating MDSC correlate with

- clinical outcome of melanoma patients treated with ipilimumab. *Cancer Immunol Immunother* **63**, 247-257 (2014).
16. Stockinger, H., Altenhoff, A. M., Arnold, K., Bairoch, A., Bastian, F., Bergmann, S., Bougueleret, L., Bucher, P., Delorenzi, M., Lane, L., Mercier, P. L., Lisacek, F., Michielin, O., Palagi, P. M., Rougemont, J., Schwede, T., Mering, C., Nimwegen, E., Walther, D., Xenarios, I., Zavolan, M., Zdobnov, E. M., Zoete, V. & Appel, R. D. Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support. *Nucleic Acids Res* **42**, W436-41 (2014).
 17. Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O. & Zoete, V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Res* **42**, W32-8 (2014).
 18. Barras, D., Chevalier, N., Zoete, V., Dempsey, R., Lapouge, K., Olayioye, M. A., Michielin, O. & Widmann, C. A WxW Motif is required for the Anticancer Activity of TAT-RasGAP317-326. *J Biol Chem* (2014).
 19. Fagerberg, T., Zoete, V., Viatte, S., Baumgaertner, P., Alves, P. M., Romero, P., Speiser, D. E. & Michielin, O. Prediction of Cross-Recognition of Peptide-HLA A2 by Melan-A-Specific Cytotoxic T Lymphocytes Using Three-Dimensional Quantitative Structure-Activity Relationships. *PLoS One* **8**, e65590 (2013).
 20. Romano, E., Pradervand, S., Paillusson, A., Weber, J., Harshman, K., Muehlethaler, K., Speiser, D., Peters, S., Rimoldi, D. & Michielin, O. Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. *Clin Cancer Res* (2013).
 21. Gautschi, O., Peters, S., Zoete, V., Aebersold-Keller, F., Strobel, K., Schwizer, B., Hirschmann, A., Michielin, O. & Diebold, J. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. *Lung Cancer* (2013).
 22. Gfeller, D., Michielin, O. & Zoete, V. SwissSidechain: a molecular and structural database of non-natural sidechains. *Nucleic Acids Res* **41**, D327-32 (2013).
 23. Tzika, E., Moura, B., Romano, E. & Michielin, O. [New therapeutic weapons in stage IV melanoma]. *Rev Med Suisse* **9**, 1095-1098 (2013).
 24. Gfeller, D., Michielin, O. & Zoete, V. Shaping the interaction landscape of bioactive molecules. *Bioinformatics* (2013).
 25. Wirth, M., Volkamer, A., Zoete, V., Rippmann, F., Michielin, O., Rarey, M. & Sauer, W. H. Protein pocket and ligand shape comparison and its application in virtual screening. *J Comput Aided Mol Des* **27**, 511-524 (2013).
 26. Wirth, M., Zoete, V., Michielin, O. & Sauer, W. H. SwissBioisostere: a database of molecular replacements for ligand design. *Nucleic Acids Res* **41**, D1137-43 (2013).
 27. Hebeisen, M., Baitsch, L., Presotto, D., Baumgaertner, P., Romero, P., Michielin, O., Speiser, D. E. & Rufer, N. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. *J Clin Invest* **123**, 1044-1056 (2013).
 28. Iancu, E. M., Gannon, P. O., Laurent, J., Gupta, B., Romero, P., Michielin, O., Romano, E., Speiser, D. E. & Rufer, N. Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients. *PLoS One* **8**, e78686 (2013).
 29. Zoete, V., Irving, M., Ferber, M., Cuendet, M. A. & Michielin, O. Structure-Based, Rational Design of T Cell Receptors. *Front Immunol* **4**, 268 (2013).
 30. Lapouge, K., Perozzo, R., Iwaszkiewicz, J., Bertelli, C., Zoete, V., Michielin, O., Scapozza, L. & Haas, D. RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family. *RNA Biol* **10**, 1031-1041 (2013).

31. Chen, S., Gfeller, D., Buth, S. A., Michielin, O., Leiman, P. G. & Heinis, C. Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids. *Chembiochem* **14**, 1316-1322 (2013).
32. Dummer, R., Goldinger, S. M., Turtzchi, C. P., Eggmann, N. B., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R., Felderer, L. & Rinderknecht, J. D. Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. *Eur J Cancer* (2013).
33. Peters, S., Michielin, O. & Zimmermann, S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. *J Clin Oncol* **31**, e341-4 (2013).
34. Demierre, N., Zoete, V., Michielin, O., Stauffer, E., Zimmermann, D. R., Betticher, D. C. & Peters, S. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? *Lung Cancer* **80**, 81-84 (2013).
35. Ding, J., Loizides-Mangold, U., Rando, G., Zoete, V., Michielin, O., Reddy, J. K., Wahli, W., Riezman, H. & Thorens, B. The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids. *Cell Rep* (2013).
36. Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza Stalder, J., Speiser, D. E., Peters, S. & Michielin, O. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. *J Clin Oncol* **30**, e156-9 (2012).
37. Johansson, M. U., Zoete, V., Michielin, O. & Guex, N. Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. *BMC Bioinformatics* **13**, 173 (2012).
38. Buey, R. M., Sen, I., Kortt, O., Mohan, R., Gfeller, D., Veprintsev, D., Kretschmar, I., Scheuermann, J., Neri, D., Zoete, V., Michielin, O., de Pereda, J. M., Akhmanova, A., Volkmer, R. & Steinmetz, M. O. Sequence determinants of a microtubule tip localization signal (MtLS). *J Biol Chem* **287**, 28227-28242 (2012).
39. Schraml, P., von Teichman, A., Mihic-Probst, D., Simcock, M., Ochsenbein, A., Dummer, R., Michielin, O., Seifert, B., Schlappi, M., Moch, H. & von Moos, R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. *Oncol Rep* **28**, 654-658 (2012).
40. Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V., Michielin, O., Muehlethaler, K., Speiser, D., Beckmann, J. S., Xenarios, I., Halazonetis, T. D., Jongeneel, C. V., Stevenson, B. J. & Antonarakis, S. E. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. *Nat Genet* **44**, 133-139 (2012).
41. Rohrig, U. F., Majjigapu, S. R., Grosdidier, A., Bron, S., Stroobant, V., Pilotte, L., Colau, D., Vogel, P., Van den Eynde, B. J., Zoete, V. & Michielin, O. Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. *J Med Chem* **55**, 5270-5290 (2012).
42. Irving, M., Zoete, V., Hebeisen, M., Schmid, D., Baumgartner, P., Guillaume, P., Romero, P., Speiser, D., Luescher, I., Rufer, N. & Michielin, O. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. *J Biol Chem* **287**, 23068-23078 (2012).
43. Baumgaertner, P., Jandus, C., Rivals, J. P., Derre, L., Lovgren, T., Baitsch, L., Guillaume, P., Luescher, I. F., Berthod, G., Matter, M., Rufer, N., Michielin, O. & Speiser, D. E. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. *Int J Cancer* **130**, 2607-2617 (2012).
44. Baitsch, L., Legat, A., Barba, L., Fuertes Marraco, S. A., Rivals, J. P., Baumgaertner, P., Christiansen-Jucht, C., Bouzourene, H., Rimoldi, D., Pircher, H., Rufer, N., Matter, M., Michielin, O. & Speiser, D. E. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. *PLoS One* **7**, e30852 (2012).

45. Ferber, M., Zoete, V. & Michielin, O. T-cell receptors binding orientation over peptide/MHC class I is driven by long-range interactions. *PLoS One* **7**, e51943 (2012).
46. Gfeller, D., Michielin, O. & Zoete, V. Expanding molecular modeling and design tools to non-natural sidechains. *J Comput Chem* **33**, 1525-1535 (2012).
47. von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlappi, M., Moch, H., Schraml, P. H., Mjhić-Probst, D., Mamot, C., Schonewolf, N. & Dummer, R. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). *Ann Oncol* **23**, 531-536 (2012).
48. Goldinger, S. M., Dummer, R., Baumgaertner, P., Mihic-Probst, D., Schwarz, K., Hammann-Haenni, A., Willers, J., Geldhof, C., Prior, J. O., Kundig, T. M., Michielin, O., Bachmann, M. F. & Speiser, D. E. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. *Eur J Immunol* **42**, 3049-3061 (2012).
49. Berthod, G., Homicsko, K., Bouchaab, H., Matter, M., Cerottini, J. P., Guggisberg, D., Speiser, D., Leyvraz, S. & Michielin, O. [Melanoma: a new therapeutic era]. *Rev Med Suisse* **7**, 1126-1130 (2011).
50. Bulliard, Y., Narvaiza, I., Bertero, A., Peddi, S., Rohrig, U. F., Ortiz, M., Zoete, V., Castro-Diaz, N., Turelli, P., Telenti, A., Michielin, O., Weitzman, M. D. & Trono, D. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. *J Virol* **85**, 1765-1776 (2011).
51. Cuendet, M. A., Zoete, V. & Michielin, O. How T cell receptors interact with peptide-MHCs: a multiple steered molecular dynamics study. *Proteins* **79**, 3007-3024 (2011).
52. Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., Harshman, K., Guipponi, M., Bukach, O., Zoete, V., Michielin, O., Muehlethaler, K., Speiser, D., Beckmann, J. S., Xenarios, I., Halazonetis, T. D., Jongeneel, C. V., Stevenson, B. J. & Antonarakis, S. E. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. *Nat Genet* (2011).
53. Rahm, N., Yap, M., Snoeck, J., Zoete, V., Munoz, M., Radespiel, U., Zimmermann, E., Michielin, O., Stoye, J. P., Ciuffi, A. & Telenti, A. Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses. *J Virol* **85**, 4173-4183 (2011).
54. Maillard, P. V., Zoete, V., Michielin, O. & Trono, D. Homology-based identification of capsid determinants that protect HIV1 from human TRIM5alpha restriction. *J Biol Chem* **286**, 8128-8140 (2011).
55. Baumgaertner, P., Jandus, C., Rivals, J. P., Derre, L., Lovgren, T., Baitsch, L., Guillaume, P., Luescher, I. F., Berthod, G., Matter, M., Rufer, N., Michielin, O. & Speiser, D. E. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. *Int J Cancer* (2011).
56. Sala, E., Guasch, L., Iwaszkiewicz, J., Mulero, M., Salvado, M. J., Blade, C., Ceballos, M., Valls, C., Zoete, V., Grosdidier, A., Garcia-Vallve, S., Michielin, O. & Pujadas, G. Identification of human IKK-2 inhibitors of natural origin (Part II): in Silico prediction of IKK-2 inhibitors in natural extracts with known anti-inflammatory activity. *Eur J Med Chem* **46**, 6098-6103 (2011).
57. Sala, E., Guasch, L., Iwaszkiewicz, J., Mulero, M., Salvado, M. J., Pinent, M., Zoete, V., Grosdidier, A., Garcia-Vallve, S., Michielin, O. & Pujadas, G. Identification of human IKK-2 inhibitors of natural origin (part I): modeling of the IKK-2 kinase domain, virtual screening and activity assays. *PLoS One* **6**, e16903 (2011).
58. Speiser, D. E., Wieckowski, S., Gupta, B., Iancu, E. M., Baumgaertner, P., Baitsch, L., Michielin, O., Romero, P. & Rufer, N. Single cell analysis reveals similar functional

- competence of dominant and nondominant CD8 T-cell clonotypes. *Proc Natl Acad Sci U S A* (2011).
59. Strasser, B., Iwaszkiewicz, J., Michielin, O. & Mayer, A. The V-ATPase proteolipid cylinder promotes the lipid-mixing stage of SNARE-dependent fusion of yeast vacuoles. *EMBO J* **30**, 4126-4141 (2011).
 60. von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlappi, M., Moch, H., Schraml, P. H., Mjhić-Probst, D., Mamot, C., Schonewolf, N. & Dummer, R. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). *Ann Oncol* (2011).
 61. Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res* **39 Suppl 2**, W270-7 (2011).
 62. Grosdidier, A., Zoete, V. & Michielin, O. Fast docking using the CHARMM force field with EADock DSS. *J Comput Chem* (2011).
 63. Zoete, V., Cuendet, M. A., Grosdidier, A. & Michielin, O. SwissParam: a fast force field generation tool for small organic molecules. *J Comput Chem* **32**, 2359-2368 (2011).
 64. Leimgruber, A., Ferber, M., Irving, M., Hussain-Kahn, H., Wieckowski, S., Derre, L., Rufer, N., Zoete, V. & Michielin, O. TCRRep 3D: an automated in silico approach to study the structural properties of TCR repertoires. *PLoS One* **6**, e26301 (2011).
 65. Derre, L., Rivals, J. P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D. & Speiser, D. E. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. *J Clin Invest* **120**, 157-167 (2010).
 66. Bulliard, Y., Narvaiza, I., Bertero, A., Peddi, S., Rohrig, U. F., Ortiz, M., Zoete, V., Castro-Diaz, N., Turelli, P., Telenti, A., Michielin, O., Weitzman, M. D. & Trono, D. Structure-function analysis points to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. *J Virol* (2010).
 67. Caballero, O. L., Zhao, Q., Rimoldi, D., Stevenson, B. J., Svobodova, S., Devalle, S., Rohrig, U. F., Pagotto, A., Michielin, O., Speiser, D., Wolchok, J. D., Liu, C., Pejovic, T., Odunsi, K., Bresseur, F., Van den Eynde, B. J., Old, L. J., Lu, X., Cebon, J., Strausberg, R. L. & Simpson, A. J. Frequent MAGE mutations in human melanoma. *PLoS One* **5**, (2010).
 68. Caballero, O. L., Zhao, Q., Rimoldi, D., Stevenson, B. J., Svobodova, S., Devalle, S., Rohrig, U. F., Pagotto, A., Michielin, O., Speiser, D., Wolchok, J. D., Liu, C., Pejovic, T., Odunsi, K., Bresseur, F., Van den Eynde, B. J., Old, L. J., Lu, X., Cebon, J., Strausberg, R. L. & Simpson, A. J. Correction: Frequent MAGE Mutations in Human Melanoma. *PLoS One* **5**, (2010).
 69. Bizzini, A., Entenza, J. M., Michielin, O., Arnold, I., Erni, B. & Moreillon, P. A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to *Streptococcus gordonii*. *Antimicrob Agents Chemother* **54**, 259-266 (2010).
 70. Liechti, L. A., Berneche, S., Bargeton, B., Iwaszkiewicz, J., Roy, S., Michielin, O. & Kellenberger, S. A combined computational and functional approach identifies new residues involved in pH-dependent gating of ASIC1a. *J Biol Chem* **285**, 16315-16329 (2010).
 71. Maillard, P. V., Zoete, V., Michielin, O. & Trono, D. Homology-based identification of capsid determinants that protect HIV1 from human TRIM5 α restriction. *J Biol Chem* (2010).
 72. Schmid, D. A., Irving, M. B., Posevitz, V., Hebeisen, M., Posevitz-Fejfar, A., Sarria, J. C., Gomez-Eerland, R., Thome, M., Schumacher, T. N., Romero, P., Speiser, D. E., Zoete, V., Michielin, O. & Rufer, N. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. *J Immunol* **184**, 4936-4946 (2010).
 73. Schupbach, T., Zoete, V., Tsakam-Sotche, B. & Michielin, O. Fourier transform convolution integrals applied to generalized Born molecular volume. *J Comput Chem* **31**, 649-659 (2010).

74. Zoete, V., Irving, M. B. & Michielin, O. MM-GBSA binding free energy decomposition and T cell receptor engineering. *J Mol Recognit* **23**, 142-152 (2010).
75. Zoete, V., Grosdidier, A., Cuendet, M. & Michielin, O. Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock. *J Mol Recognit* **23**, 457-461 (2010).
76. Rohrig, U. F., Awad, L., Grosdidier, A., Larrieu, P., Stroobant, V., Colau, D., Cerundolo, V., Simpson, A. J., Vogel, P., Van den Eynde, B. J., Zoete, V. & Michielin, O. Rational design of indoleamine 2,3-dioxygenase inhibitors. *J Med Chem* **53**, 1172-1189 (2010).
77. Bulliard, Y., Turelli, P., Rohrig, U. F., Zoete, V., Mangeat, B., Michielin, O. & Trono, D. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. *J Virol* **83**, 12611-12621 (2009).
78. Rohrig, U. F., Grosdidier, A., Zoete, V. & Michielin, O. Docking to heme proteins. *J Comput Chem* **30**, 2305-2315 (2009).
79. Bulliard, Y., Turelli, P., Rohrig, U. F., Zoete, V., Mangeat, B., Michielin, O. & Trono, D. Functional Analysis and Structural Modeling of Human APOBEC3G Reveals the Role of Evolutionarily Conserved Elements in HIV-1 and Alu Inhibition. *J Virol* (2009).
80. Schupbach, T., Zoete, V., Tsakam-Sotche, B. & Michielin, O. Fourier transform convolution integrals applied to generalized Born molecular volume. *J Comput Chem* (2009).
81. Prior, J. O., Montemurro, M., Orcurto, M. V., Michielin, O., Luthi, F., Benhattar, J., Guillou, L., Elsig, V., Stupp, R., Delaloye, A. B. & Leyvraz, S. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. *J Clin Oncol* **27**, 439-445 (2009).
82. Grosdidier, A., Zoete, V. & Michielin, O. Blind docking of 260 protein-ligand complexes with EADock 2.0. *J Comput Chem* (2009).
83. Grosdidier, A., Zoete, V. & Michielin, O. Blind docking of 260 protein-ligand complexes with EADock 2.0. *J Comput Chem* **30**, 2021-2030 (2009).
84. Hornitschek, P., Lorrain, S., Zoete, V., Michielin, O. & Fankhauser, C. Inhibition of the shade avoidance response by formation of non-DNA binding bHLH heterodimers. *EMBO J* **28**, 3893-3902 (2009).
85. Zoete, V., Grosdidier, A. & Michielin, O. Docking, virtual high throughput screening and in silico fragment-based drug design. *J Cell Mol Med* **13**, 238-248 (2009).
86. Zoete, V., Grosdidier, A. & Michielin, O. Docking, virtual high throughput screening and in silico fragment-based drug design. *J Cell Mol Med* (2009).
87. Capendeguy, O., Iwaszkiewicz, J., Michielin, O. & Horisberger, J. D. The fourth extracellular loop of the alpha subunit of Na,K-ATPase. Functional evidence for close proximity with the second extracellular loop. *J Biol Chem* **283**, 27850-27858 (2008).
88. Chodanowski, P., Grosdidier, A., Feytmans, E. & Michielin, O. Local alignment refinement using structural assessment. *PLoS ONE* **3**, e2645 (2008).
89. Michielin, O., Rufer, N., Romero, P., Laurent, J., Cerottini, J. P., Gugisberg, D., Leyvraz, S. & Speiser, D. [New developments in cancer immunotherapy]. *Rev Med Suisse* **4**, 1248-1251 (2008).
90. Cuendet, M. A. & Michielin, O. Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex. *Biophys J* **95**, 3575-3590 (2008).

91. Rochat, B., Zoete, V., Grosdidier, A., von Grunigen, S., Marull, M. & Michielin, O. In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. *Biopharm Drug Dispos* **29**, 103-118 (2008).
92. Voelter, V., Rufer, N., Reynard, S., Greub, G., Brookes, R., Guillaume, P., Grosjean, F., Fagerberg, T., Michielin, O., Rowland-Jones, S., Pinilla, C., Leyvraz, S., Romero, P. & Appay, V. Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. *Int Immunol* **20**, 1087-1096 (2008).
93. Derre, L., Bruyninx, M., Baumgaertner, P., Ferber, M., Schmid, D., Leimgruber, A., Zoete, V., Romero, P., Michielin, O., Speiser, D. E. & Rufer, N. Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. *Proc Natl Acad Sci U S A* **105**, 15010-15015 (2008).
94. Zhang, K. L., Mangeat, B., Ortiz, M., Zoete, V., Trono, D., Telenti, A. & Michielin, O. Model structure of human APOBEC3G. *PLoS ONE* **2**, e378 (2007).
95. Grosdidier, A., Zoete, V. & Michielin, O. EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization. *Proteins* **67**, 1010-1025 (2007).
96. Derre, L., Ferber, M., Touvrey, C., Devevre, E., Zoete, V., Leimgruber, A., Romero, P., Michielin, O., Levy, F. & Speiser, D. E. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. *J Immunol* **179**, 7635-7645 (2007).
97. Buttica, C., Michielin, O., Wyniger, J., Telenti, A. & Rothenberger, S. Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. *J Virol* **81**, 1502-1505 (2007).
98. Zoete, V. & Michielin, O. Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex. *Proteins* **67**, 1026-1047 (2007).
99. Zoete, V., Grosdidier, A. & Michielin, O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. *Biochim Biophys Acta* **1771**, 915-925 (2007).
100. Feige, J. N., Gelman, L., Rossi, D., Zoete, V., Metivier, R., Tudor, C., Anghel, S. I., Grosdidier, A., Lathion, C., Engelborghs, Y., Michielin, O., Wahli, W. & Desvergne, B. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. *J Biol Chem* **282**, 19152-19166 (2007).
101. Michielin, O. [Application of molecular modeling to new therapeutic cancer approaches]. *Bull Cancer* **94**, 763-768 (2007).
102. Alves, P. M., Viatte, S., Fagerberg, T., Michielin, O., Bricard, G., Bouzourene, H., Vuilleumier, H., Kruger, T., Givel, J. C., Levy, F., Speiser, D. E., Cerottini, J. C. & Romero, P. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. *Cancer Immunol Immunother* **56**, 1795-1805 (2007).
103. Michalik, L., Zoete, V., Krey, G., Grosdidier, A., Gelman, L., Chodanowski, P., Feige, J. N., Desvergne, B., Wahli, W. & Michielin, O. Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior. *J Biol Chem* **282**, 9666-9677 (2007).
104. Stupp, R., Pica, A., Mirimanoff, R. O. & Michielin, O. [A practical guide for the management of gliomas]. *Bull Cancer* **94**, 817-822 (2007).
105. Yip, Y. L., Zoete, V., Scheib, H. & Michielin, O. Structural assessment of single amino acid mutations: application to TP53 function. *Hum Mutat* **27**, 926-937 (2006).

106. Fagerberg, T., Cerottini, J. C. & Michielin, O. Structural prediction of peptides bound to MHC class I. *J Mol Biol* **356**, 521-546 (2006).
107. Capendeguy, O., Chodanowski, P., Michielin, O. & Horisberger, J. D. Access of extracellular cations to their binding sites in Na,K-ATPase: role of the second extracellular loop of the alpha subunit. *J Gen Physiol* **127**, 341-352 (2006).
108. Colombetti, S., Fagerberg, T., Baumgartner, P., Chapatte, L., Speiser, D. E., Rufer, N., Michielin, O. & Levy, F. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. *J Immunol* **176**, 6560-6567 (2006).
109. Aublin, A., Ciofani, M., Willkomm, N., Hamrouni, A., Szymczak-Workman, A. L., Takahashi, T., Sandjeu, Y., Guillaume, P., Vignali, D. A., Michielin, O., Zuniga-Pflucker, J. C. & Maryanski, J. L. A natural structural variant of the mouse TCR beta-chain displays intrinsic receptor function and antigen specificity. *J Immunol* **177**, 8587-8594 (2006).
110. Cebecauer, M., Guillaume, P., Mark, S., Michielin, O., Boucheron, N., Bezard, M., Meyer, B. H., Segura, J. M., Vogel, H. & Luescher, I. F. CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers. *J Biol Chem* **280**, 23820-23828 (2005).
111. Michielin, O., Blanchet, J. S., Fagerberg, T., Valmori, D., Rubio-Godoy, V., Speiser, D., Ayyoub, M., Alves, P., Luescher, I., Gairin, J. E., Cerottini, J. C. & Romero, P. Tinkering with nature: the tale of optimizing peptide based cancer vaccines. *Cancer Treat Res* **123**, 267-291 (2005).
112. De Los Rios, P., Cecconi, F., Pretre, A., Dietler, G., Michielin, O., Piazza, F. & Juanico, B. Functional dynamics of PDZ binding domains: a normal-mode analysis. *Biophys J* **89**, 14-21 (2005).
113. Filges, I., Zaman, K., Michielin, O., Vulliamoz, D., Perey, L. & Stupp, R. [Present chemoprevention and future vision]. *Rev Med Suisse* **1**, 1343-6, 1349 (2005).
114. Suarez, M., Haenni, M., Canarelli, S., Fisch, F., Chodanowski, P., Servis, C., Michielin, O., Freitag, R., Moreillon, P. & Mermod, N. Structure-function characterization and optimization of a plant-derived antibacterial peptide. *Antimicrob Agents Chemother* **49**, 3847-3857 (2005).
115. Michielin, O., Udry, E., Periard, D., Matzinger, O., Lobrinus, J. A. & Stupp, R. Irinotecan-induced interstitial pneumonia. *Lancet Oncol* **5**, 322-324 (2004).
116. Hauert, J., Fernandez-Carneado, J., Michielin, O., Mathieu, S., Grell, D., Schapira, M., Spertini, O., Mutter, M., Tuchscherer, G. & Kovacsovics, T. A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation. *Chembiochem* **5**, 856-864 (2004).
117. Horisberger, J. D., Kharoubi-Hess, S., Guennoun, S. & Michielin, O. The fourth transmembrane segment of the Na,K-ATPase alpha subunit: a systematic mutagenesis study. *J Biol Chem* **279**, 29542-29550 (2004).
118. Li, C., Grosdidier, A., Crambert, G., Horisberger, J. D., Michielin, O. & Geering, K. Structural and functional interaction sites between Na,K-ATPase and FXYD proteins. *J Biol Chem* **279**, 38895-38902 (2004).
119. Dietrich, P. Y., Le Gal, F. A., Dutoit, V., Pittet, M. J., Trautman, L., Zippelius, A., Cognet, I., Widmer, V., Walker, P. R., Michielin, O., Guillaume, P., Connerotte, T., Jotereau, F., Coulie, P. G., Romero, P., Cerottini, J. C., Bonneville, M. & Valmori, D. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. *J Immunol* **170**, 5103-5109 (2003).
120. Doucey, M. A., Goffin, L., Naeher, D., Michielin, O., Baumgartner, P., Guillaume, P., Palmer, E. & Luescher, I. F. CD3 delta establishes a functional link between the T cell receptor and CD8. *J Biol Chem* **278**, 3257-3264 (2003).

121. Zoete, V., Michielin, O. & Karplus, M. Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors. *J Comput Aided Mol Des* **17**, 861-880 (2003).
122. Schwitzgebel, V. M., Mamin, A., Brun, T., Ritz-Laser, B., Zaiko, M., Maret, A., Jornayvaz, F. R., Theintz, G. E., Michielin, O., Melloul, D. & Philippe, J. Aggenesis of human pancreas due to decreased half-life of insulin promoter factor 1. *J Clin Endocrinol Metab* **88**, 4398-4406 (2003).
123. Bernimoulin, M. P., Zeng, X. L., Abbal, C., Giraud, S., Martinez, M., Michielin, O., Schapira, M. & Spertini, O. Molecular basis of leukocyte rolling on PSGL-1. Predominant role of core-2 O-glycans and of tyrosine sulfate residue 51. *J Biol Chem* **278**, 37-47 (2003).
124. Zoete, V., Michielin, O. & Karplus, M. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. *J Mol Biol* **315**, 21-52 (2002).
125. Michielin, O., Zoete, V., Gierasch, T. M., Eckstein, J., Napper, A., Verdine, G. & Karplus, M. Conformational analysis of a stereochemically complete set of cis-enediol peptide analogues. *J Am Chem Soc* **124**, 11131-11141 (2002).
126. Michielin, O. & Karplus, M. Binding Free Energy Differences in a TCR-Peptide-MHC Complex Induced by a Peptide Mutation: A Simulation Analysis. *J. Mol. Biol.* **324**, 547-569 (2002).
127. Michielin, O. & Karplus, M. Binding free energy differences in a TCR-peptide-MHC complex induced by a peptide mutation: a simulation analysis. *J Mol Biol* **324**, 547-569 (2002).
128. Romero, P., Valmori, D., Pittet, M. J., Zippelius, A., Rimoldi, D., Levy, F., Dutoit, V., Ayyoub, M., Rubio-Godoy, V., Michielin, O., Guillaume, P., Batard, P., Luescher, I. F., Lejeune, F., Lienard, D., Rufer, N., Dietrich, P. Y., Speiser, D. E. & Cerottini, J. C. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. *Immunol Rev* **188**, 81-96 (2002).
129. Sliz, P., Michielin, O., Cerottini, J. C., Luescher, I., Romero, P., Karplus, M. & Wiley, D. C. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. *J Immunol* **167**, 3276-3284 (2001).
130. Michielin, O., Luescher, I. & Karplus, M. Modeling of the TCR-MHC-peptide complex. *J Mol Biol* **300**, 1205-1235 (2000).
131. Michielin, O., Vergère, G. & Ramsden, J. J. Myristoylation-Induced Compaction of a Membrane-Binding Protein. *J Am Chem Soc* **121**, 6523-6526 (1999).
132. Bour, H., Michielin, O., Bouso, P., Cerottini, J. C. & MacDonald, H. R. Dramatic influence of V beta gene polymorphism on an antigen-specific CD8+ T cell response in vivo. *J Immunol* **162**, 4647-4656 (1999).
133. Kessler, B., Michielin, O., Blanchard, C. L., Apostolou, I., Delarbre, C., Gachelin, G., Gregoire, C., Malissen, B., Cerottini, J. C., Wurm, F., Karplus, M. & Luescher, I. F. T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivative. *J Biol Chem* **274**, 3622-3631 (1999).
134. Michielin, O., Ramsden, J. J. & Vergeres, G. Unmyristoylated MARCKS-related protein (MRP) binds to supported planar phosphatidylcholine membranes. *Biochim Biophys Acta* **1375**, 110-116 (1998).
135. Michielin, O. & Phillipson, P. Map Dynamics Study of the Lorenz Equation. *Int J Bif Chaos* **7**, 373-382 (1997).
136. Michielin, O. & Phillipson, P. Construction of Poincaré maps for multiply periodic and chaotic flows. *Phys Lett A* **188**, 309-316 (1994).

Book Chapters

1. Chapter “Melanoma targeted therapies”: Romano E, Michielin O. In “Successes and Limitations of Targeted Cancer Therapy”, Krager
2. Chapter 10: *Molecular Modeling of Proteins: From Simulations to Drug Design Applications*. Zoete V, Cuendet M, Röhrig UF, Grosdidier A, Michielin O. In “Bioinformatics. A Swiss Perspective”. Editors Appel RD and Feytmans E, World Scientific Publishing Co., Singapore.
3. Chapter 19: *Molecular Dynamics-based Free Energy Simulations*. Cuendet M, Zoete V, Michielin O. In “Computational Structural Biology”. Editors Schwede T and Peitsch M, World Scientific Publishing Co., Singapore.